newsfilter
← Latest News
Business Wire·

Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics

Highlights Expected Special Cash Dividend of Approximately $70 Million, and Upside of CVR and Ownership of Combined Company Sesen Bio, Inc. (NASDAQ:SESN) today issued the following statement reiterating the Company's